Covidien divests U.S. radiopharmacies
This article was originally published in The Gray Sheet
Diversified device and drug maker sells its domestic network of 37 radiopharmacies to Triad Isotopes for undisclosed terms, the firm announces Dec. 17. Divestiture of the business, with $180 million in annual sales, "is consistent with Covidien's strategy to streamline its portfolio and reallocate resources to its faster-growing, higher-margin businesses, where the company has or can develop a global competitive advantage," the firm explains
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.